Palvella to present QTORIN rapamycin study results at vascular congress

April 20, 2026 7:30 AM

Palvella Therapeutics Inc. (NASDAQ: PVLA) announced that two abstracts highlighting results from Phase 3 SELVA and Phase 2 TOIVA studies ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found